Your session is about to expire
← Back to Search
APL-2 + Pembrolizumab +/- Bevacizumab for Ovarian Cancer
Study Summary
This trial is studying the safety and effect of C3 complement inhibitor APL-2 (Pegcetacoplan) alone and in combination with Pembrolizumab, as well as APL-2 in combination with both Bevacizumab and Pembrolizumab in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer with symptomatic malignant effusion (ascites or pleural effusion).
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am currently on medication for an infection.I have been treated for an autoimmune disease in the last 3 months.You are expected to live for at least 3 more months.I have a serious heart condition.My cancer has returned in the ovary, fallopian tube, or peritoneum, or I have both ovarian and uterine cancer.I am 18 years old or older.I don't have any health issues that could affect the trial's results.I haven't taken steroids or immunosuppressants in the last 7 days.I am not on any cancer treatment or in a drug/device trial within the last 3 weeks.I am able to care for myself and perform daily activities.I can take my medication by myself.You need to have a negative pregnancy test if you can have a baby.Your test results need to be within certain ranges.I haven't taken bevacizumab, pembrolizumab, or similar drugs in the last 9 weeks.I have had fluid drained from my abdomen or chest, or have a drainage tube, within the last 4 weeks.I am willing to get vaccinations if needed for the trial.I have no known allergies or adverse reactions to bevacizumab or pembrolizumab.
- Group 1: Cohort 2B-2 (pegcetacoplan, pembrolizumab, bevacizumab)
- Group 2: Cohort 2B-3 (bevacizumab)
- Group 3: Cohort 2B-1 (pegcetacoplan, pembrolizumab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any safety risks associated with using Pembrolizumab?
"The safety of Pembrolizumab was assessed at a score of 2, as this is Phase 2 trial with supporting data on the drug's security but no information yet regarding its effectiveness."
Has Pembrolizumab been evaluated in any other scientific experiments?
"Currently, there are over 1300 investigations into the effects of Pembrolizumab with 212 in Phase 3. Out of a total 52409 sites studying this medication worldwide, several can be found in Pittsburgh, Pennsylvania."
To what maladies is Pembrolizumab typically employed?
"Pembrolizumab is an approved treatment option for those with unresectable melanoma and other conditions such as microsatellite instability high, locally advanced nonsquamous non-small cell lung cancer, or a heightened chance of recurrence."
Does this research still have openings for participants?
"According to the details provided on clinicaltrials.gov, this trial is no longer in its recruitment phase; it was first posted on December 15th 2022 and last updated October 31st 2022. However, there are currently 5,224 other trials actively seeking patients."
How many participants have subscribed to this clinical research?
"Recruitment for this particular medical trial has ended, as the last edit was recorded on October 31st 2022. Currently, 3922 trials are actively trying to recruit patients with primary peritoneal adenocarcinoma and another 1302 studies require participants for Pembrolizumab."
Share this study with friends
Copy Link
Messenger